Chris Oliver
Plus aucun poste en cours
Profil
Chris Oliver joined Synageva BioPharma Corp.
in 2002 and currently serves as Director of Operations.
Prior to joining Synageva BioPharma, he worked with Cobb-Vantress, Inc. Previously, Mr. Oliver held various management positions at Con Agra.
He has 25 years of experience in production operations.
Mr. Oliver received a BS degree in Agriculture from the University of Georgia.
Anciens postes connus de Chris Oliver
| Sociétés | Poste | Fin |
|---|---|---|
Cobb-Vantress, Inc.
 Cobb-Vantress, Inc. Agricultural Commodities/MillingProcess Industries Cobb-Vantress, Inc. operates a poultry research firm. It specializes in the development, production, and sale of broiler breeding stock. The company was founded in 1986 and is headquartered in Siloam Springs, AR. | Corporate Officer/Principal | - |
Synageva BioPharma Corp. /Old/
 Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Directeur des opérations | - |
Formation de Chris Oliver
| University of Georgia | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Synageva BioPharma Corp. /Old/
Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Health Technology |
Cobb-Vantress, Inc.
Cobb-Vantress, Inc. Agricultural Commodities/MillingProcess Industries Cobb-Vantress, Inc. operates a poultry research firm. It specializes in the development, production, and sale of broiler breeding stock. The company was founded in 1986 and is headquartered in Siloam Springs, AR. | Process Industries |
